207 related articles for article (PubMed ID: 16162969)
1. Genetic determinants of cancer drug efficacy and toxicity: practical considerations and perspectives.
Candelaria M; Taja-Chayeb L; Arce-Salinas C; Vidal-Millan S; Serrano-Olvera A; Dueñas-Gonzalez A
Anticancer Drugs; 2005 Oct; 16(9):923-33. PubMed ID: 16162969
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy.
Bosch TM
Methods Mol Biol; 2008; 448():63-76. PubMed ID: 18370231
[TBL] [Abstract][Full Text] [Related]
3. Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.
Bosch TM; Meijerman I; Beijnen JH; Schellens JH
Clin Pharmacokinet; 2006; 45(3):253-85. PubMed ID: 16509759
[TBL] [Abstract][Full Text] [Related]
4. Inherited variations in drug-metabolizing enzymes: significance in clinical oncology.
Iyer L
Mol Diagn; 1999 Dec; 4(4):327-33. PubMed ID: 10671643
[TBL] [Abstract][Full Text] [Related]
5. Introduction.
;
Invest New Drugs; 2005 Dec; 23(6):511. PubMed ID: 16391895
[No Abstract] [Full Text] [Related]
6. Cancer pharmacogenetics.
Marsh S; McLeod HL
Br J Cancer; 2004 Jan; 90(1):8-11. PubMed ID: 14710198
[TBL] [Abstract][Full Text] [Related]
7. Pharmacogenetics: a tool for individualizing antineoplastic therapy.
Innocenti F; Iyer L; Ratain MJ
Clin Pharmacokinet; 2000 Nov; 39(5):315-25. PubMed ID: 11108431
[TBL] [Abstract][Full Text] [Related]
8. Cancer pharmacogenomics: current and future applications.
Watters JW; McLeod HL
Biochim Biophys Acta; 2003 Mar; 1603(2):99-111. PubMed ID: 12618310
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenetics of cytotoxic drugs.
Daly AK; Hall AG
Expert Rev Anticancer Ther; 2001 Aug; 1(2):301-8. PubMed ID: 12113035
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of anti-cancer drugs: State of the art and implementation - recommendations of the French National Network of Pharmacogenetics.
Quaranta S; Thomas F
Therapie; 2017 Apr; 72(2):205-215. PubMed ID: 28262261
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics and cancer chemotherapy.
Iyer L; Ratain MJ
Eur J Cancer; 1998 Sep; 34(10):1493-9. PubMed ID: 9893619
[TBL] [Abstract][Full Text] [Related]
12. [The biological point of view on pharmacogenetics of anticancer agents in colorectal cancer].
Laurent-Puig P; Lièvre A; Ducreux M; Loriot MA
Bull Cancer; 2008 Oct; 95(10):935-42. PubMed ID: 19004723
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacogenetics of capecitabine and its metabolites following replicate administration of two 500 mg tablet formulations.
Queckenberg C; Erlinghagen V; Baken BC; Van Os SH; Wargenau M; Kubeš V; Peroutka R; Novotný V; Fuhr U
Cancer Chemother Pharmacol; 2015 Nov; 76(5):1081-91. PubMed ID: 26242222
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of excision repair complementation group 1, glutathione S-transferase, thymidylate synthase and uridine diphosphate glucuronosyl transferase 1A1 polymorphisms predictive for treatment outcome in patients with advanced gastric cancer treated with FOLFOX or FOLFIRI.
Seo BG; Kwon HC; Oh SY; Lee S; Kim SG; Kim SH; Han H; Kim HJ
Oncol Rep; 2009 Jul; 22(1):127-36. PubMed ID: 19513514
[TBL] [Abstract][Full Text] [Related]
15. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?
Maitland ML; Vasisht K; Ratain MJ
Trends Pharmacol Sci; 2006 Aug; 27(8):432-7. PubMed ID: 16815558
[TBL] [Abstract][Full Text] [Related]
16. [Genetic polymorphisms related to fluoropyrimidine sensitivity and toxicity].
Terashima M
Gan To Kagaku Ryoho; 2008 Jul; 35(7):1101-4. PubMed ID: 18633250
[TBL] [Abstract][Full Text] [Related]
17. Variants in the dihydropyrimidine dehydrogenase, methylenetetrahydrofolate reductase and thymidylate synthase genes predict early toxicity of 5-fluorouracil in colorectal cancer patients.
Kristensen MH; Pedersen PL; Melsen GV; Ellehauge J; Mejer J
J Int Med Res; 2010; 38(3):870-83. PubMed ID: 20819423
[TBL] [Abstract][Full Text] [Related]
18. Determinants of chemosensitivity in gastric cancer.
Park DJ; Lenz HJ
Curr Opin Pharmacol; 2006 Aug; 6(4):337-44. PubMed ID: 16777480
[TBL] [Abstract][Full Text] [Related]
19. Dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms and their association with 5-fluorouracil/leucovorin chemotherapy in colorectal cancer.
Zhu AX; Puchalski TA; Stanton VP; Ryan DP; Clark JW; Nesbitt S; Charlat O; Kelly P; Kreconus E; Chabner BA; Supko JG
Clin Colorectal Cancer; 2004 Feb; 3(4):225-34. PubMed ID: 15025795
[TBL] [Abstract][Full Text] [Related]
20. [Pharmacogenomic approaches for prevention of drug toxicity in cancer chemotherapy].
Hasegawa Y
Gan To Kagaku Ryoho; 2003 Mar; 30(3):325-33. PubMed ID: 12669388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
